Skip to main page content
U.S. flag

An official website of the United States government

Dot gov

The .gov means it’s official.
Federal government websites often end in .gov or .mil. Before sharing sensitive information, make sure you’re on a federal government site.

Https

The site is secure.
The https:// ensures that you are connecting to the official website and that any information you provide is encrypted and transmitted securely.

Access keys NCBI Homepage MyNCBI Homepage Main Content Main Navigation
Case Reports
. 2021 Sep;85(3):366-368.
doi: 10.1111/cod.13857. Epub 2021 Apr 23.

Severe adverse drug reaction in SARS-CoV-2 infection: AGEP induced by ceftriaxone and confirmed by patch test

Luca Stingeni  1 , Daniela Francisci  2 , Leonardo Bianchi  1 , Katharina Hansel  1 , Marta Tramontana  1 , Francesco Di Candilo  2 , Massimo Raffaele Mannarino  3 , Matteo Pirro  3
Affiliations
Case Reports

Severe adverse drug reaction in SARS-CoV-2 infection: AGEP induced by ceftriaxone and confirmed by patch test

Luca Stingeni et al. Contact Dermatitis. 2021 Sep.
No abstract available

Keywords: AGEP/TEN overlap; COVID-19; SARS-CoV-2 infection; ceftriaxone; patch test; severe cutaneous adverse reaction.

PubMed Disclaimer

Conflict of interest statement

All authors have no conflicts of interests to report.

Figures

FIGURE 1
FIGURE 1
(A) Extensive erythematous eruption with (B) flaccid superficial pustules resembling blisters and (C) superficial detachment. (D) Positive patch test (++) with a pustular reaction pattern to ceftriaxone (5% in pet., D4)
See this image and copyright information in PMC

References

    1. Gelincik A, Brockow K, Çelik GE, et al. Diagnosis and management of the drug hypersensitivity reactions in coronavirus disease 19: an EAACI position paper. Allergy. 2020;75(11):2775‐2793. - PMC - PubMed
    1. Martinez‐Lopez A, Cuenca‐Barrales C, Montero‐Vilchez T, Molina‐Leyva A, Arias‐Santiago S. Review of adverse cutaneous reactions of pharmacologic interventions for COVID‐19: a guide for the dermatologist. J Am Acad Dermatol. 2020;83(6):1738‐1748. - PMC - PubMed
    1. Robustelli Test E, Vezzoli P, Carugno A, et al. Acute generalized exanthematous pustulosis with erythema multiforme‐like lesions in a COVID‐19 woman. J Eur Acad Dermatol Venereol. 2020;34(9):e457‐e459. - PMC - PubMed
    1. Haraszti S, Sendil S, Jensen N. Delayed presentation of acute generalized Exanthematous pustulosis following treatment with cefepime in a patient with COVID‐19 without the use of Hydroxychloroquine. Am J Case Rep. 2020;24(21):e926901. - PMC - PubMed
    1. Torres‐Navarro I, Abril‐Pérez C, Roca‐Ginés J, Sánchez‐Arráez J, Botella‐Estrada R. A case of cefditoren‐induced acute generalized exanthematous pustulosis during COVID‐19 pandemics. Severe cutaneous adverse reactions are an issue. J Eur Acad Dermatol Venereol. 2020;34(10):e537‐e539. - PMC - PubMed

Publication types

MeSH terms